Symbol="CALT"
AssetType="Common Stock"
Name="Calliditas Therapeutics"
Description="Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing pharmaceutical products for treatments in orphan indications with an initial focus on kidney and liver diseases. The company is headquartered in Stockholm, Sweden."
CIK="1795579"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="KUNGSBRON 1, C8, STOCKHOLM, SE"
FiscalYearEnd="December"
LatestQuarter="2022-12-31"
MarketCapitalization="424277000"
EBITDA="None"
PERatio="None"
PEGRatio="None"
BookValue="None"
DividendPerShare="0"
DividendYield="0"
EPS="-1.45"
RevenuePerShareTTM="0"
ProfitMargin="-0.416"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.148"
ReturnOnEquityTTM="-0.538"
RevenueTTM="0"
GrossProfitTTM="787678000"
DilutedEPSTTM="-1.45"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="2.848"
AnalystTargetPrice="53.33"
TrailingPE="-"
ForwardPE="8.77"
PriceToSalesRatioTTM="13.24"
PriceToBookRatio="7.39"
EVToRevenue="1.225"
EVToEBITDA="-0.753"
Beta="1.354"
num_52WeekHigh="25.64"
num_52WeekLow="10.82"
num_50DayMovingAverage="20.12"
num_200DayMovingAverage="18.77"
SharesOutstanding="26836000"
DividendDate="None"
ExDividendDate="None"
symbol="CALT"
open="15.84"
high="16.10"
low="15.68"
price="15.79"
volume="28410.00"
latest_trading_day="2023-07-06"
previous_close="17.84"
change="-2.05"
change_percent="-11.4910%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="20"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="80"
Volume_recent_avg="10615"
Change_recent_avg="0.03"
Delta_recent_avg="1.0"
Variance_recent_avg="0.5"
Change_ratio_recent_avg="0.13"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="80"
Aroon_momentum_negative="20"
image_negative_thumbnail_id_1="142"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0034.jpeg"
image_negative_thumbnail_id_2="1113"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0146.jpeg"
image_neutral_thumbnail_id_1="560"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0039.jpeg"
image_neutral_thumbnail_id_2="559"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0040.jpeg"
image_positive_thumbnail_id_1="966"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0128.jpeg"
image_positive_thumbnail_id_2="960"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0122.jpeg"
image_professor_thumbnail_id_1="1170"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0004.jpeg"
image_professor_thumbnail_id_2="1174"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0008.jpeg"
